A survey of human papillomavirus 16 antibodies in patients with epithelial cancers

Howard Strickler, M. H. Schiffman, K. V. Shah, C. S. Rabkin, J. T. Schiller, S. Wacholder, B. Clayman, R. P. Viscidi

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Human papillomavirus (HPV), particularly HPV 16, is linked to the development of cervical cancer. However, the role of HPV 16 in a number of extra-cervical epithelial tumours is controversial. To assess exposure to HPV 16 in patients with different cancers, we conducted a large serosurvey of 905 patients with 21 types of tumours and measured IgG to HPV 16 virus-like particles (VLPs) using a well characterized enzyme linked immunosorbent assay (ELISA). Patients with cervical cancer were considered 'positive controls', as about half were expected to be specifically HPV 16-related. A non-cancer study group consisting of 48 patients with endocrine disorders (eg diabetes) was also tested. HPV 16 antibody prevalence was highest in patients with cancers of the cervix (52% ± 7%), vulva (27% ± 9%), vagina (27% ± 13%) and penis (63% ± 16%). Seroprevalence was much lower in the non-cancer group (4% ± 3%) and all other cancer patients: uterus (9% ± 4%); ovary (4% ± 3%); testis (5% ± 4%); prostate (6% ± 4%); squamous carcinoma (6% ± 3%) and adenocarcinoma (4% ± 3%) of the lung; rectum (2% ± 2%); pancreas (8% ± 4%); colon (2% ± 2%); stomach (0%); oesophagus (8% ± 4%); buccal cavity (12% ± 5%); breast (10% ± 4%); non-melanomatous (9% ± 6%) and melanomatous (6% ± 3%) skin tumours; bladder (8% ± 4%); and kidney (2% ± 2%). The results confirm the strong relation of HPV with several lower anogenital tract tumours, but, at least in this population, fail to identify additional epithelial tumours associated with high seroprevalence of HPV 16 VLP antibodies.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalEuropean Journal of Cancer Prevention
Volume7
Issue number4
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Human papillomavirus 16
Antibodies
Papillomaviridae
Neoplasms
Uterine Cervical Neoplasms
Seroepidemiologic Studies
Virion
Uterine Neoplasms
Vulva
Cheek
Penis
Vagina
Surveys and Questionnaires
Rectum
Esophagus
Testis
Prostate
Pancreas
Squamous Cell Carcinoma
Ovary

Keywords

  • Antibodies
  • Cancer
  • Carcinoma
  • HPV 16
  • Human papillomavirus
  • Virus-like- particles
  • VLP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Strickler, H., Schiffman, M. H., Shah, K. V., Rabkin, C. S., Schiller, J. T., Wacholder, S., ... Viscidi, R. P. (1998). A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. European Journal of Cancer Prevention, 7(4), 305-313. https://doi.org/10.1097/00008469-199808000-00006

A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. / Strickler, Howard; Schiffman, M. H.; Shah, K. V.; Rabkin, C. S.; Schiller, J. T.; Wacholder, S.; Clayman, B.; Viscidi, R. P.

In: European Journal of Cancer Prevention, Vol. 7, No. 4, 1998, p. 305-313.

Research output: Contribution to journalArticle

Strickler, H, Schiffman, MH, Shah, KV, Rabkin, CS, Schiller, JT, Wacholder, S, Clayman, B & Viscidi, RP 1998, 'A survey of human papillomavirus 16 antibodies in patients with epithelial cancers', European Journal of Cancer Prevention, vol. 7, no. 4, pp. 305-313. https://doi.org/10.1097/00008469-199808000-00006
Strickler, Howard ; Schiffman, M. H. ; Shah, K. V. ; Rabkin, C. S. ; Schiller, J. T. ; Wacholder, S. ; Clayman, B. ; Viscidi, R. P. / A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. In: European Journal of Cancer Prevention. 1998 ; Vol. 7, No. 4. pp. 305-313.
@article{0726df53f5384b72a9c19ded3658b293,
title = "A survey of human papillomavirus 16 antibodies in patients with epithelial cancers",
abstract = "Human papillomavirus (HPV), particularly HPV 16, is linked to the development of cervical cancer. However, the role of HPV 16 in a number of extra-cervical epithelial tumours is controversial. To assess exposure to HPV 16 in patients with different cancers, we conducted a large serosurvey of 905 patients with 21 types of tumours and measured IgG to HPV 16 virus-like particles (VLPs) using a well characterized enzyme linked immunosorbent assay (ELISA). Patients with cervical cancer were considered 'positive controls', as about half were expected to be specifically HPV 16-related. A non-cancer study group consisting of 48 patients with endocrine disorders (eg diabetes) was also tested. HPV 16 antibody prevalence was highest in patients with cancers of the cervix (52{\%} ± 7{\%}), vulva (27{\%} ± 9{\%}), vagina (27{\%} ± 13{\%}) and penis (63{\%} ± 16{\%}). Seroprevalence was much lower in the non-cancer group (4{\%} ± 3{\%}) and all other cancer patients: uterus (9{\%} ± 4{\%}); ovary (4{\%} ± 3{\%}); testis (5{\%} ± 4{\%}); prostate (6{\%} ± 4{\%}); squamous carcinoma (6{\%} ± 3{\%}) and adenocarcinoma (4{\%} ± 3{\%}) of the lung; rectum (2{\%} ± 2{\%}); pancreas (8{\%} ± 4{\%}); colon (2{\%} ± 2{\%}); stomach (0{\%}); oesophagus (8{\%} ± 4{\%}); buccal cavity (12{\%} ± 5{\%}); breast (10{\%} ± 4{\%}); non-melanomatous (9{\%} ± 6{\%}) and melanomatous (6{\%} ± 3{\%}) skin tumours; bladder (8{\%} ± 4{\%}); and kidney (2{\%} ± 2{\%}). The results confirm the strong relation of HPV with several lower anogenital tract tumours, but, at least in this population, fail to identify additional epithelial tumours associated with high seroprevalence of HPV 16 VLP antibodies.",
keywords = "Antibodies, Cancer, Carcinoma, HPV 16, Human papillomavirus, Virus-like- particles, VLP",
author = "Howard Strickler and Schiffman, {M. H.} and Shah, {K. V.} and Rabkin, {C. S.} and Schiller, {J. T.} and S. Wacholder and B. Clayman and Viscidi, {R. P.}",
year = "1998",
doi = "10.1097/00008469-199808000-00006",
language = "English (US)",
volume = "7",
pages = "305--313",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A survey of human papillomavirus 16 antibodies in patients with epithelial cancers

AU - Strickler, Howard

AU - Schiffman, M. H.

AU - Shah, K. V.

AU - Rabkin, C. S.

AU - Schiller, J. T.

AU - Wacholder, S.

AU - Clayman, B.

AU - Viscidi, R. P.

PY - 1998

Y1 - 1998

N2 - Human papillomavirus (HPV), particularly HPV 16, is linked to the development of cervical cancer. However, the role of HPV 16 in a number of extra-cervical epithelial tumours is controversial. To assess exposure to HPV 16 in patients with different cancers, we conducted a large serosurvey of 905 patients with 21 types of tumours and measured IgG to HPV 16 virus-like particles (VLPs) using a well characterized enzyme linked immunosorbent assay (ELISA). Patients with cervical cancer were considered 'positive controls', as about half were expected to be specifically HPV 16-related. A non-cancer study group consisting of 48 patients with endocrine disorders (eg diabetes) was also tested. HPV 16 antibody prevalence was highest in patients with cancers of the cervix (52% ± 7%), vulva (27% ± 9%), vagina (27% ± 13%) and penis (63% ± 16%). Seroprevalence was much lower in the non-cancer group (4% ± 3%) and all other cancer patients: uterus (9% ± 4%); ovary (4% ± 3%); testis (5% ± 4%); prostate (6% ± 4%); squamous carcinoma (6% ± 3%) and adenocarcinoma (4% ± 3%) of the lung; rectum (2% ± 2%); pancreas (8% ± 4%); colon (2% ± 2%); stomach (0%); oesophagus (8% ± 4%); buccal cavity (12% ± 5%); breast (10% ± 4%); non-melanomatous (9% ± 6%) and melanomatous (6% ± 3%) skin tumours; bladder (8% ± 4%); and kidney (2% ± 2%). The results confirm the strong relation of HPV with several lower anogenital tract tumours, but, at least in this population, fail to identify additional epithelial tumours associated with high seroprevalence of HPV 16 VLP antibodies.

AB - Human papillomavirus (HPV), particularly HPV 16, is linked to the development of cervical cancer. However, the role of HPV 16 in a number of extra-cervical epithelial tumours is controversial. To assess exposure to HPV 16 in patients with different cancers, we conducted a large serosurvey of 905 patients with 21 types of tumours and measured IgG to HPV 16 virus-like particles (VLPs) using a well characterized enzyme linked immunosorbent assay (ELISA). Patients with cervical cancer were considered 'positive controls', as about half were expected to be specifically HPV 16-related. A non-cancer study group consisting of 48 patients with endocrine disorders (eg diabetes) was also tested. HPV 16 antibody prevalence was highest in patients with cancers of the cervix (52% ± 7%), vulva (27% ± 9%), vagina (27% ± 13%) and penis (63% ± 16%). Seroprevalence was much lower in the non-cancer group (4% ± 3%) and all other cancer patients: uterus (9% ± 4%); ovary (4% ± 3%); testis (5% ± 4%); prostate (6% ± 4%); squamous carcinoma (6% ± 3%) and adenocarcinoma (4% ± 3%) of the lung; rectum (2% ± 2%); pancreas (8% ± 4%); colon (2% ± 2%); stomach (0%); oesophagus (8% ± 4%); buccal cavity (12% ± 5%); breast (10% ± 4%); non-melanomatous (9% ± 6%) and melanomatous (6% ± 3%) skin tumours; bladder (8% ± 4%); and kidney (2% ± 2%). The results confirm the strong relation of HPV with several lower anogenital tract tumours, but, at least in this population, fail to identify additional epithelial tumours associated with high seroprevalence of HPV 16 VLP antibodies.

KW - Antibodies

KW - Cancer

KW - Carcinoma

KW - HPV 16

KW - Human papillomavirus

KW - Virus-like- particles

KW - VLP

UR - http://www.scopus.com/inward/record.url?scp=0031691753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031691753&partnerID=8YFLogxK

U2 - 10.1097/00008469-199808000-00006

DO - 10.1097/00008469-199808000-00006

M3 - Article

VL - 7

SP - 305

EP - 313

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 4

ER -